Key Takeaways
- Soleno Therapeutics focuses on therapies for rare diseases, with a product targeting hyperphagia in Prader-Willi syndrome.
- The company’s first commercial product, VYKAT XR, activates KATP channels to manage appetite-related issues in affected patients.
- Prader-Willi syndrome is a rare genetic disorder that leads to severe appetite regulation problems and obesity risks.
Company Overview and Product Details
Soleno Therapeutics, Inc. (NasdaqCM:SLNO) is dedicated to developing innovative therapeutics for rare diseases. The company’s primary focus is its first commercial product, VYKAT XR (diazoxide choline), which is specifically designed to treat hyperphagia in individuals aged four and older diagnosed with Prader-Willi syndrome (PWS).
VYKAT XR is administered once daily in an extended-release tablet form, aiming to manage excessive appetite and associated behaviors linked to PWS. This rare genetic disorder is characterized by complex neurobehavioral and metabolic challenges, often resulting in increased food-seeking behavior, a lack of satiety, and the accumulation of excess body fat, leading to obesity.
The active ingredient in VYKAT XR, diazoxide choline, functions as a potent activator of ATP-sensitive potassium (KATP) channels in the body. These channels are crucial in regulating various physiological processes, including those that, when dysregulated, can worsen the symptoms of PWS. Addressing these dysregulations is key in managing the disorder and improving patients’ quality of life.
The company continues to advance its therapeutic offerings while demonstrating a commitment to addressing the unique needs of those with rare health challenges, such as patients with PWS. As it builds on its foundational product, Soleno Therapeutics aims to expand its reach within the biotechnology industry, focusing on innovative solutions for underserved medical conditions.
The content above is a summary. For more details, see the source article.